SynAct Pharma Publishes Q3 2026 Interim Results

LUND, SE / ACCESS Newswire / November 3, 2026 / SynAct Pharma AB (publ) ("SynAct")(STO:SYNACT), a clinical-stage biotechnology company focused on treating inflammation through a novel therapeutic approach known as "pro-resolution", today publishes …